deferoxamine has been researched along with Seizures in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a patient undergoing chronic hemodialysis who developed a neurologic syndrome consisting of seizures, progressive myoclonus, and mild dementia and who responded to chelation therapy with deferoxamine mesylate." | 3.67 | Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. ( Corwin, HL; Mayor, GH; Sprague, SM; Tanner, CM; Wilson, RS, 1986) |
| "In the first case, paranoid delusions, visual hallucinations, seizures and deteriorating speech followed each dialysis treatment with DFO." | 1.28 | Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. ( McCauley, J; Sorkin, MI, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yong, RL | 1 |
| Holmes, DT | 1 |
| Sreenivasan, GM | 1 |
| Fasano, A | 1 |
| Colosimo, C | 1 |
| Miyajima, H | 1 |
| Tonali, PA | 1 |
| Re, TJ | 1 |
| Bentivoglio, AR | 1 |
| Rubin, JJ | 1 |
| Willmore, LJ | 1 |
| Erasmus, RT | 1 |
| Kusnir, J | 1 |
| Stevenson, WC | 1 |
| Lobo, P | 1 |
| Herman, MM | 1 |
| Wills, MR | 1 |
| Savory, J | 1 |
| McCauley, J | 1 |
| Sorkin, MI | 1 |
| Sprague, SM | 1 |
| Corwin, HL | 1 |
| Wilson, RS | 1 |
| Mayor, GH | 1 |
| Tanner, CM | 1 |
6 other studies available for deferoxamine and Seizures
| Article | Year |
|---|---|
Aluminum toxicity due to intravenous injection of boiled methadone.
Topics: Adult; Aluminum; Ataxia; Chelation Therapy; Deferoxamine; Dysarthria; Humans; Male; Methadone; Poiso | 2006 |
Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability.
Topics: Brain; Ceruloplasmin; Deferoxamine; Diabetes Mellitus; Disease Progression; Family; Female; Heredode | 2008 |
Prevention of iron-induced epileptiform discharges in rats by treatment with antiperoxidants.
Topics: Animals; Cerebral Cortex; Deferoxamine; Electroencephalography; Evoked Potentials; Ferrous Compounds | 1980 |
Hyperaluminemia associated with liver transplantation and acute renal failure.
Topics: Acute Kidney Injury; Albumins; Aluminum; Ammonia; Antidotes; Chelating Agents; Coma; Deferoxamine; D | 1995 |
Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
Topics: Aged; Aluminum Hydroxide; Deferoxamine; Hallucinations; Humans; Male; Memory Disorders; Middle Aged; | 1989 |
Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
Topics: Aluminum; Deferoxamine; Dementia; Female; Humans; Kidney Failure, Chronic; Middle Aged; Myoclonus; R | 1986 |